Matching articles for "Abilify Maintena"
Aripiprazole with Digital Ingestion Tracking (Abilify MyCite)
The Medical Letter on Drugs and Therapeutics • January 28, 2019; (Issue 1564)
Monitoring adherence of psychiatric patients to
oral medication may be especially difficult. The
FDA has approved Abilify MyCite (Otsuka/Proteus),
an aripiprazole tablet with an embedded sensor
that tracks...
Monitoring adherence of psychiatric patients to
oral medication may be especially difficult. The
FDA has approved Abilify MyCite (Otsuka/Proteus),
an aripiprazole tablet with an embedded sensor
that tracks when patients take the medication. It is
indicated for treatment of adults with schizophrenia,
bipolar disorder, or major depressive disorder. Abilify MyCite is the first drug with a digital ingestion tracking
system to be approved in the US.
Drugs for Psychiatric Disorders
The Medical Letter on Drugs and Therapeutics • June 1, 2013; (Issue 130)
Drugs are not the only treatment for psychiatric illness.
Psychotherapy remains an important component
in the management of these disorders, and cognitive
behavioral therapy (CBT) can be used for many...
Drugs are not the only treatment for psychiatric illness.
Psychotherapy remains an important component
in the management of these disorders, and cognitive
behavioral therapy (CBT) can be used for many of
them as well. Electroconvulsive therapy (ECT) has a
long history of efficacy and safety when drugs are
ineffective or cannot be used.
Long-Acting Injectable Aripiprazole (Abilify Maintena) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • April 29, 2013; (Issue 1415)
An extended-release injectable formulation of the
second-generation antipsychotic aripiprazole
(Abilify) has been approved by the FDA (Abilify
Maintena – Otsuka/Lundbeck) for once-monthly treatment of...
An extended-release injectable formulation of the
second-generation antipsychotic aripiprazole
(Abilify) has been approved by the FDA (Abilify
Maintena – Otsuka/Lundbeck) for once-monthly treatment of schizophrenia. It is the fourth second-generation
antipsychotic to become available in a
long-acting parenteral formulation. Long-acting parenteral
antipsychotics, given at intervals of 2-4
weeks, are generally used for patients with a history
of relapse due to poor adherence to oral maintenance
therapy.